SusanLernerCohnMD

Pediatric Hematology & Oncology • Chicago, IL

Pediatric Solid Tumor Oncology

Professor of Pediatrics, University of Chicago Medicine

Overview of Dr. Cohn

I am a board certified pediatric oncologist. I have devoted my career to caring for children with neuroblastoma and conducting clinical and translational research focused on understanding the biologic underpinnings of high-risk neuroblastoma to identify new therapeutic targets. The long-term goal is to develop more effective treatment based on tumor biology and host genetics. Through my leadership positions in the Children’s Oncology Group (COG), I have worked with my colleagues to translate laboratory findings into clinical trials for children with neuroblastoma. I have also led efforts to develop risk classification algorithms in the International Neuroblastoma Risk Group (INRG) Task Force and the COG. In addition, I have worked closely with Dr. Andrew Pearson from the UK and Dr. Samuel Volchenboum from the University of Chicago to create the INRG Data Commons. This Data Commons currently contains data on >22,700 patients with neuroblastoma from around the world that are available to the neuroblastoma community for research studies. We are now working closely with Dr. Volchenboum to develop the Pediatric Cancer Data Commons (PCDC) and have integrated the neuroblastoma data into this platform.

Office
900 E 57th Street
KCBD Rm 5100
Chicago, IL 60637
Book by Phone+1(855) 699-4289
Is this information wrong?

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Pediatric Hematology/Oncology, 1984 - 1987
Michael Reese Hospital and Medical CenterResidency, Pediatrics, 1980 - 1984
University of Illinois College of MedicineClass of 1980
Northwestern UniversityB.A., 1972 - 1976

Certifications & Licensure

IL State Medical License 1981 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Top Cancer Doctor Newsweek and Castle Connolly, 2015-2024
Top Doctor in the Chicago Metro Area Castle Connolly, 2006, 2008, 2010, 2012, 2014, 2016, 2018-2024
Top Doctor in the Chicago Metro Area Chicago Magazine, 2006, 2008, 2010, 2012, 2014, 2016, 2018-2024
Lifetime Achievement Award Advances in Neuroblastoma Research, 2023
AACR-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research AACR, 2019
The Samuel Spector Award for Mentorship Department of Pediatrics, University of Chicago, 2018
Pediatric Oncology Award American Society of Clinical Oncology (ASCO), 2016
Fellow American Society of Clinical Oncology (FASCO), 2016
American Society of Clinical Oncology (ASCO) Pediatric Oncology Award ASCO, 2016
Pediatrics Faculty Physician Peer Role Model Nominee University of Chicago, 2013
Pritzker Scholar University of Chicago, 2012
Chicago Innovator Award Association for Women in Science (AWIS), 2012
Joseph P. Brenneman Award The Chicago Pediatric Society, 2009
SIOP Award in the Discipline of Basic Science Society for Industrial and Organizational Psychology, Inc., 2004
Nominated for the best clinical professor award Northwestern University Medical School, 1999
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

N99-02: Melphalan and Buthionine Sulfoximine Start of enrollment: 2001 Aug 01
Completed
Phase 1
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Start of enrollment: 2004 Mar 25
Recruiting
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma Start of enrollment: 2005 Dec 01
Completed
Phase 1
N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma Start of enrollment: 2006 Dec 01
Completed
Phase 1
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
Recruiting
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma Start of enrollment: 2009 Dec 01
Completed
Phase 1
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma Start of enrollment: 2008 Feb 04
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma Start of enrollment: 2010 Mar 01
Completed
Phase 1
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Start of enrollment: 2010 Oct 04
Active, not recruiting
Phase 1
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma Start of enrollment: 2013 Feb 04
Active, not recruiting
Phase 1
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16
Active, not recruiting
Phase 1
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Start of enrollment: 2014 Jul 01
Completed
Phase 2
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
Join now to see all

Publications & Presentations

PubMed

Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study.
Cohn, S. L., Erica C Kaye, Jesse Smith, Yiwang Zhou, Rochelle Bagatell, Justin N Baker, Susan L Cohn, Lisa R Diller, Julia L Glade Bender, M Meaghan Granger, Araz Mara...> ;Cancer. 2024 Apr 1
Impact of Risk-Based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the childhood cancer survivor study.
Cohn, S. L., Danielle Novetsky Friedman, Pamela J Goodman, Wendy M Leisenring, Lisa R Diller, Susan L Cohn, Rebecca M Howell, Susan A Smith, Emily S Tonorezos, Suzanne...> ;Journal of the National Cancer Institute. 2024 Mar 9
1 citations
Persistence of Racial and Ethnic Disparities in Risk and Survival for Patients with Neuroblastoma over Two Decades.
Cohn, S. L., Mohansrinivas Chennakesavalu, Caileigh Pudela, Mark A Applebaum, Sang Mee Lee, Yan Che, Arlene Naranjo, Julie R Park, Samuel L Volchenboum, Tara O Henders...> ;EJC Paediatric Oncology. 2023 Dec 1
1 citations
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Strat...
Hannah G Bender, Meredith S Irwin, Michael D Hogarty, Robert Castleberry, John M Maris, Pei-Chi Kao, Fan F Zhang, Arlene Naranjo, Wendy B London, Cohn, S. L., Susan L ...> ;Journal of Clinical Oncology. 2023 Jun 10
Multimodality treatment for recurrent neuroblastoma in the central nervous system.
Ami V Desai, Lena Elmuti, Christine Cahaney, Raymond M De Guzman, Keri A Streby, Cohn, S. L., Susan L Cohn> ;Pediatric Blood & Cancer. 2023 Apr 1
3 citations
Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study.
Danielle Novetsky Friedman, Pamela J Goodman, Wendy M Leisenring, Lisa R Diller, Susan L Cohn, Rebecca M Howell, Susan A Smith, Emily S Tonorezos, Suzanne L Wolden, Jo...> ;Journal of Clinical Oncology. 2023 Mar 10
7 citations
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
Ami V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, Arlene Naranjo, Wendy B London, Sheena C Tenney, Mitchell Diccianni, Jacquelyn A Hank, Marguerite T Parisi, Barry ...> ;Journal of Clinical Oncology. 2022 Dec 10
6 citations
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease.
Ami V Desai, Mark A Applebaum, Theodore G Karrison, Akosua Oppong, Cindy Yuan, Katherine R Berg, Kyle MacQuarrie, Elizabeth Sokol, Anurekha G Hall, Navin Pinto, Ian Wo...> ;Cancer. 2022 Aug 1
1 citations
Rethinking high-risk neuroblastoma treatment.
Susan L Cohn, Andrew D J Pearson> ;Pediatric Blood & Cancer. 2022 Aug 1
3 citations
Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group.
Anoop Mayampurath, Siddhi Ramesh, Diana Michael, Liu Liu, Nicholas Feinberg, Meaghan Granger, Arlene Naranjo, Susan L Cohn, Samuel L Volchenboum, Mark A Applebaum> ;JCO Clinical Cancer Informatics. 2021 Dec 1
24 citations
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
Riyue Bao, Stefani Spranger, Kyle M. Hernandez, Yuanyuan Zha, Peter Pytel, Jason J. Luke, Thomas F. Gajewski, Samuel L. Volchenboum, Susan L. Cohn, Ami V. Desai> ;Journal for Immunotherapy of Cancer. 2021 Jul 1
5 citations
Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From...
Asuka Kawano, Florette K. Hazard, Bill Chiu, Arlene Naranjo, Brian LaBarre, Wendy B. London, Michael D. Hogarty, Susan L. Cohn, John M. Maris, Julie R. Park, Julie M. ...> ;The American Journal of Surgical Pathology. 2021 Aug 1
14 citations
Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research
Alejandro Plana, Brian Furner, Monica Palese, Nicole Dussault, Suzi Birz, Luca Graglia, Maura A. Kush, James Nicholson, Stefanie Hecker-Nolting, Nathalie Gaspar, Marei...> ;JCO Clinical Cancer Informatics. 2021 Oct 18
142 citations
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.
Meredith S. Irwin, Arlene Naranjo, Fan F Zhang, Susan L. Cohn, Wendy B. London, Julie M. Gastier-Foster, Nilsa C. Ramirez, Ruthann Pfau, Shalini C. Reshmi, Elizabeth W...> ;Journal of Clinical Oncology. 2021 Jul 28
26 citations
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report ...
Steven G. DuBois, M. Meaghan Granger, Susan Groshen, Denice D. Tsao-Wei, Lingyun Ji, Anasheh Shamirian, Scarlett Czarnecki, Fariba Goodarzian, Rachel Berkovich, Hiroyu...> ;Journal of Clinical Oncology. 2021 Jul 16
4 citations
Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma.
Skye Balyasny, Sang Mee Lee, Ami V. Desai, Samuel L. Volchenboum, Arlene Naranjo, Julie R. Park, Wendy B. London, Susan L. Cohn, Mark A. Applebaum> ;JAMA Network Open. 2021 Jul 1
78 citations
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
Alice L. Yu, Andrew L. Gilman, M. Fevzi Ozkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan, Jacquelyn A. Hank, Ayse Batova, Wendy B. London, Sheena C. Tenney, ...> ;Clinical Cancer Research. 2021 Apr 15
24 citations
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group pro...
Lucas Moreno, Dongjing Guo, Meredith S. Irwin, Frank Berthold, Michael D. Hogarty, Takehiko Kamijo, Daniel A. Morgenstern, Claudia Pasqualini, Shifra Ash, Ulrike Pötsc...> ;Pediatric Blood & Cancer. 2021 Mar 1
31 citations
Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future.
Wayne H. Liang, Sara M. Federico, Wendy B. London, Arlene Naranjo, Meredith S. Irwin, Samuel L. Volchenboum, Susan L. Cohn> ;JCO Clinical Cancer Informatics. 2020 Oct 15
27 citations
Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer.
Jennifer W. Mack, Hajime Uno, Clare J. Twist, Rochelle Bagatell, Abby R. Rosenberg, Araz Marachelian, M. Meaghan Granger, Julia Glade Bender, Justin N. Baker, Julie R....> ;Journal of Pain and Symptom Management. 2020 Oct 1
Reply to K. Beiske et al
Elizabeth A. Sokol, Ami V. Desai, Mark A. Applebaum, Dominique Valteau-Couanet, Julie R. Park, Andrew D.J. Pearson, Gudrun Schleiermacher, Meredith S. Irwin, Michael D...> ;Journal of Clinical Oncology. 2020 Sep 15
6 citations
Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients.
Erin K. Barr, Kathryn Laurie, Kristen Wroblewski, Mark A. Applebaum, Susan L. Cohn> ;Pediatric Blood & Cancer. 2020 Jul 25
3 citations
Subclinical tuberculosis and adverse infant outcomes in pregnant women with HIV.
H M Rickman, Susan L. Cohn, Sanjay G. Lala, Z. Waja, Nicole Salazar-Austin, Jennifer D. Hoffmann, Kelly E. Dooley, Christopher J. Hoffmann, Richard E. Chaisson, Neil A...> ;The International Journal of Tuberculosis and Lung Disease. 2020 Jul 1
1 citations
Paraneoplastic opsoclonus myoclonus syndrome associated with inflammatory myofibroblastic tumor in a pediatric patient.
Karyn Gerstle, Amir Siddiqui, Jefree J. Schulte, Susan L. Cohn> ;Pediatric Blood & Cancer. 2020 May 30
24 citations
The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project
Veronica Moroz, David Machin, Barbara Hero, Ruth Ladenstein, Frank Berthold, Paige Kao, Yaa Obeng, Andrew D.J. Pearson, Susan L. Cohn, Wendy B. London> ;Pediatric Blood & Cancer. 2020 May 30
Join now to see all

Journal Articles

Children's Oncology Group's 2013 blueprint for research: neuroblastoma
Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KM, Hogarty M; COG Neuroblastoma Committee, Pediatr Blood Cancer, 1/1/2013
Two Cases of Localized Neuroblastoma with Multiple Segmental Chromosomal Alterations and Metastatic Progression
Morales La Madrid A, Nall MB, Ouyang K, Minor A, Raca G, Kent P, Miller I, Schleiermacher G, Janoueix-Lerosey I, and Cohn SL, Ped Blood Cancer, 1/1/2013
Progression-Free Survival of Two Cases of High-risk Neuroblastoma with Refractory/Relapsed Disease Following Surgery Alone
Sokol E, Haut PR, Gosiengfiao Y, Feinstein K, Pytel P, and Cohn SL, Ped Blood Cancer, 1/1/2013
Semiquantitative MIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma A Children's Oncology Group (COG) Study
Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca J, Maris J, Cohn SL, McGrady P, Matthay KK, J Nucl Med, 1/1/2013
A Pilot Study of Tandem High Dose Chemotherapy with Stem Cell Rescue as Consolidation for High Risk Neuroblastoma: Children's Oncology Group study ANBL00P1
Seif AE, Naranjo A, , Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA, Bone Marrow Transplant, 1/1/2013
Neuroblastoma - Undifferentiated Subtype, Prognostic Significance of Prominent Nucleolar Formation and Expression of MYC and MYCN Protein: A Report from the Children's...
Wang LL, Suganunma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MB, Gastier-Foster J, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, and Shimada H, Cancer, 1/1/2013
A Randomized Trial of Purged versus Non-Purged Autologous Peripheral Blood Stem Cell Transplant for High-Risk Neuroblastoma
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, LaQuaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, an..., Lancet Oncol, 1/1/2013
Individualized Therapies for Pediatric Cancer
Bates S, Thiele C, Cohn S, Clinical Cancer Research FOCUS, 5/18/2012
New Aspects of Neuroblastoma Treatment: ASPHO 2011 Symposium Review
Zage PE, Louis CU, and Cohn SL, Pediatr Blood Cancer, 1/1/2012
Genetically InFormed Therapies- a GIFT for children with cancer
Thiele CJ and Cohn SL, Clin Cancer Res, 1/1/2012
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma
Morales La Madrid A, Campbell N, Smith S, Cohn SL, and Salgia R, Target Oncol, 1/1/2012
Opsoclonusmyoclonus and anti-Hu positive limbic encephalitis in a patient with neuroblastoma
Morales LaMadrid A, Rubin CM, Kohrman M, Pytel P, and Cohn SL, Pediatr Blood Cancer, 1/1/2012
Sorafenib Inhibits Neuroblastoma Cell Proliferation and Signaling, Blocks Angiogenesis, and Impairs Tumor Growth
Kakodkar NC, Peddinti RR, Tian Y, Guerrero LJ, Chlenski A, Yang Q, Salwen HR, Maitland M, and Cohn SL, Ped Blood Cancer, 1/1/2012
Outcome Following Surgery Alone or with Restricted Use of Chemotherapy for Patients with Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641
Strother DR, London WB, Schmidt ML, Brodeur G et al for the Children's Oncology Group, J Clin Oncol, 1/1/2012
Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma
Ostler KR, Yang Q, Looney TJ, et al, Cancer Res, 1/1/2012
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
Schleiermacher G, Mosseri V, London WB, Maris JM, Brodeur GM et al, Br J Cancer, 1/1/2012
A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants, a Children's Oncology Group Study
Nuchtern JG, London WB, Barnewolt CE,Naranjo A, McGrady, Geiger JD, Cohn SL, Shamberger RC, Ann Surg, 1/1/2012
Locoregional MYCN-amplified Neuroblastoma: Case Report and Review of the Literature
Morales La Madrid A, Volchenboum S, Gastier-Foster JM, Pyatt R, Liu D, Pytel P, Lavarino C, Rodriguez E, and Cohn SL, Ped Blood Cancer, 1/1/2012
Advances in Pediatric Oncology
Cohn SL, SoCRA Source, 1/1/2011
Phase II Study of Irinotecan + Temozolomide in Children with Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study
Bagatell R, London WB, Wagner LM, Voss S, Reynolds CP, Stewart C, Gelfand M, Maris JM, Kretschmar C, Cohn SL, J Clin Oncol, 1/1/2011
Racial and Ethnic Disparities in Risk and Survival in Children with Neuroblastoma: A Children's Oncology Group (COG) Study
Henderson TO, Bhatia S, Pinto N, London WB, McGrady P, Crotty C, Sun C-L, and Cohn SL, J Clin Oncol, 1/1/2011
Changes over three decades in the prognostic influence of age in patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project
Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V, Ladenstein R, De Bernardi B, Rubie H, Berthold F, Matthay KK, Monclair T, Ambros PF, Pearson ADJ, Cohn SL, an..., Eur J Cancer, 1/1/2011
Radiological Guidelines for Staging of Neuroblastic Tumors: A consensus Report from the Imaging Committee of the International Neuroblastoma Risk Group Project
Brisse H, McCarville B, Granata C, Kanegawa K, Krug B, Wooton-Gorges S, Giamarile F, Levington V, Shulkin B, Kaneko M, Monclari T, Sarnacki S, Cohn SL, Hero B, Matthay..., Radiology, 1/1/2011
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) Project
London WB, Castel V, Monclair T, Ambros PF, Pearson ADJ, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T, and Matthay KK, J Clin Oncol, 1/1/2011
ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux
Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue, C, Murray J et al, J Natl Cancer Res, 1/1/2011
Join now to see all

Grant Support

Targeting DNA Double Strand Break (DSB) Repair Pathways in NeuroblastomaHyundai Hope on Wheels2020–2023
5-hydroxymethylcytosine-based Biomarkers for Children with NeuroblastomaThe Super Jake Foundation2019–2023
Pediatric Cancer Data CommonsSt. Baldrick’s Foundation2019–2022
ITM 2.0: Advancing Translational Science in Metropolitan ChicagoNIH/NCATS2017–2022
Genome-Wide 5hmC Profiling of Neuroblastoma Tumors and Patient Cell Free DNAAlex's Lemonade Stand Foundation2017–2019
MELK, A New Therapeutic Target for NeuroblastomaHyundai Hope on Wheels2017–2019
Children's Oncology GroupNCI2012–2019
The Role Of Sparc In Neuroblastoma AngiogenesisNational Institute Of Neurological Disorders And Stroke2007
The Role Of Sparc In Neuroblastoma AngiogenesisNational Institute Of Neurological Disorders And Stroke2004–2006
Pediatric Oncology GroupNational Cancer Institute1999–2002
Elav-Like Proteins In NeuroblastomaNational Cancer Institute1997–2000
Molecular Mechanisms Of Differentiation In NeuroblastomaNational Cancer Institute1990–1994

Committees

Member, Board of Directors, St. Baldrick's Foundation 2017 - 2023
Member, Board of Directors, Conquer Cancer Foundation (ASCO) 2017 - 2022

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

University of Chicago Medical CenterChicago, Illinois
Comer Childrens HospitalChicago, Illinois

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Coventry Carelink Health Plans PPO
Coventry Health Care PPO Platinum
Coventry Missouri - HMO/POS
Coventry Virginia - HMO
First Health PPO
Great West PPO
HealthLink PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment